2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial. (September 2015) - Taieb, J.